Markets
BSE See NSE See 38,040.57
15.12 (0.04%)

Glenmark to launch higher strength version of oral antiviral FabiFlu

Anthony Fernandes / Article rating: 4.7

Global pharma major, Glenmark Pharmaceuticals announced on Thursday that it is launching a 400 mg version of oral antiviral FabiFlu, for the treatment of mild to moderate COVID-19 in India. Glenmark Pharmaceuticals was the first company in the country to have received the regulator’s approval for 400 mg dosage form.

12345678910Last

DSIJ MINDSHARE

12345Last